3-(2-氧代吡咯烷)丙酸 | 77191-38-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 中文名称: 3-(2-氧代吡咯烷)丙酸
• 英文名称: 3-(2-oxopyrrolidin-1-yl)propionic acid
• 英文别名: 3-(2-oxo-pyrrolidino)-propionic acid；3-(2-Oxo-pyrrolidino)-propionsaeure；3-(2-Oxo-pyrrolidin-1-yl)-propionic acid；3-(2-oxo-1-pyrrolidinyl)propionic acid；3-(2-oxopyrrolidin-1-yl)propanoic acid；3-(2'-pyrrolidone)-propionic acid
• CAS: 77191-38-9
• 化学式: C₇H₁₁NO₃
• mdl: MFCD05237379
• 分子量: 157.169
• InChiKey: XOMYTIUVNSWEAI-UHFFFAOYSA-N

物化性质

• 沸点：
  373.7±25.0 °C(Predicted)
• 密度：
  1.257±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -0.7
• 重原子数：
  11
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.714
• 拓扑面积：
  57.6
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 危险等级：
  IRRITANT
• 危险品标志：
  Xi
• 海关编码：
  2933790090
• 危险性防范说明：
  P305+P351+P338
• 危险性描述：
  H319

反应信息

• 作为反应物：
  描述：

  3-(2-氧代吡咯烷)丙酸 在 sodium methylate 、 N,N'-羰基二咪唑 、 magnesium chloride 作用下， 以 四氢呋喃 、 甲醇 为溶剂， 生成 3-(2,6-Dichloro-phenyl)-5-[2-(2-oxo-pyrrolidin-1-yl)-ethyl]-isoxazole-4-carboxylic acid ethyl ester
  参考文献：
  名称：

  Novel isoxazole carboxamides as growth hormone secretagogue receptor (GHS-R) antagonists

  摘要：

  Novel isoxazole carboxamides have been identified as growth hormone secretagogue receptor (GHS-R) antagonists. Substituent modification off the 5-position of the isoxazole ring led to analogues with potent binding affinity and functional antagonism of GHS-R. A potent analogue (32) with high aqueous solubility and good GPCR selectivity was also identified as a potential pharmacological tool for in vivo studies. (C) 2004 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2004.06.060
• 作为产物：
  描述：

  1-(2-氯乙基)吡咯烷-2-酮 在 盐酸 、 sodium hydroxide 、 水 、 乙腈 作用下， 生成 3-(2-氧代吡咯烷)丙酸
  参考文献：
  名称：

  Reppe et al., Justus Liebigs Annalen der Chemie, 1955, vol. 596, p. 1,211

  摘要：

  DOI：

文献信息

• [EN] INHIBITORS OF APOL1 AND USE OF THE SAME<br/>[FR] INHIBITEURS D'APOL1 ET LEUR UTILISATION
  申请人：VERTEX PHARMA

  公开号：WO2021252859A1

  公开（公告）日：2021-12-16

  The disclosure provides at least one compound, deuterated derivative, or pharmaceutically acceptable salt chosen from compounds of formula (I), deuterated derivatives thereof, and pharmaceutically acceptable salts of any of the foregoing, compositions comprising the same, and methods of making and using the same, including use in treating APOL1 mediated kidney disease.

  本公开提供了至少一种化合物、重氢化衍生物或药用可接受的盐，选自公式(I)化合物、其重氢化衍生物以及任何前述物质的药用可接受的盐，包含同一的组成物，以及制造和使用同一的方法，包括用于治疗APOL1介导的肾脏疾病。
• [EN] MODULATORS OF AMYLOID BETA.<br/>[FR] MODULATEURS DE LA PROTÉINE ?-AMYLOÏDE
  申请人：ASTRAZENECA AB

  公开号：WO2010053438A1

  公开（公告）日：2010-05-14

  The present invention relates to novel compounds of formula I and therapeutically acceptable salts thereof, their pharmaceutical compositions, processes for making them and their use as therapeutic methods for treatment and/or prevention of various diseases. In particular the invention relates to compounds, which inhibit the Aβ40 and Aβ42 production, increase the Aβ37 and Aβ38 production and maintain the Notch signaling and will be used for treatment and/or prevention of Aβ-related pathologies such as Alzheimer's disease, Downs syndrome and β-amyloid angiopathy, such as but not limited to cerebral amyloid angiopathy, hereditary cerebral hemorrhage, disorders associated with cognitive impairment, such as but not limited to MCI ("mild cognitive impairment"), Alzheimer's disease, memory loss, attention deficit symptoms associated with Alzheimer's disease, neurodegeneration associated with diseases such as Alzheimer's disease or dementia including dementia of mixed vascular and degenerative origin, pre-senile dementia, senile dementia and dementia associated with Parkinson's disease, progressive supranuclear palsy or cortical basal degeneration.

  本发明涉及式I的新化合物及其治疗上可接受的盐，它们的药物组合物，制造它们的方法以及它们作为治疗和/或预防各种疾病的治疗方法的使用。特别是，本发明涉及抑制Aβ40和Aβ42产生，增加Aβ37和Aβ38产生并维持Notch信号传导的化合物，并将用于治疗和/或预防与Aβ相关的病理，如阿尔茨海默病、唐氏综合症和β-淀粉样蛋白血管病，例如但不限于脑淀粉样血管病、遗传性脑出血、与认知障碍相关的疾病，例如但不限于MCI（“轻度认知障碍”）、阿尔茨海默病、记忆丧失、与阿尔茨海默病相关的注意力缺陷症状、与阿尔茨海默病或包括混合血管和退行性来源的痴呆在内的疾病相关的神经退行性变、早老性痴呆、老年性痴呆和与帕金森病、进行性核上瘫或皮层基底退行性变相关的痴呆。
• INHIBITORS OF FATTY ACID AMIDE HYDROLASE
  申请人：INFINITY PHARMACEUTICALS, INC.

  公开号：US20150368278A1

  公开（公告）日：2015-12-24

  The present invention provides compounds, and pharmaceutically acceptable compositions thereof, encompassed by any of formulae (I), (II), (III), (IV), (V), or (VI), or subgenera thereof. The present invention also provides methods for treating an FAAH mediated disease, disorder or condition by administering a therapeutically effective amount of a compound or composition comprising a compound of any of formulae (I), (II), (III), (IV), (V), or (VI), or subgenera thereof, to a patient in need thereof. Additionally, the present invention provides methods for inhibiting FAAH by administering a therapeutically effective amount of a compound or composition comprising a compound of any of formulae (I), (II), (III), (IV), (V), or (VI), or subgenera thereof, to a patient in need thereof.

  本发明提供了由任何公式（I）、（II）、（III）、（IV）、（V）或（VI）中的任何化合物及其药学上可接受的组合物所包含的范围，或其亚属所包含的范围。本发明还提供了通过向需要的患者投与任何公式（I）、（II）、（III）、（IV）、（V）或（VI）中的任何化合物或其组合物的治疗有效量来治疗FAAH介导的疾病、紊乱或症状的方法。此外，本发明提供了通过向需要的患者投与任何公式（I）、（II）、（III）、（IV）、（V）或（VI）中的任何化合物或其组合物的治疗有效量来抑制FAAH的方法。
• PYRROLIDINE DERIVATIVES
  申请人：Knust Henner

  公开号：US20110144081A1

  公开（公告）日：2011-06-16

  The present invention relates to compounds of formula wherein R 1 , R 2 , R 3 , R 4 , Z, and n are as defined herein or to a pharmaceutically active salt thereof. Compounds of the invention are high potential NK-3 receptor antagonists for the treatment of depression, pain, psychosis, Parkinson's disease, schizophrenia, anxiety and attention deficit hyperactivity disorder (ADHD).

  本发明涉及以下式中的化合物，其中R1、R2、R3、R4、Z和n如本文所定义，或其药用活性盐。本发明的化合物是治疗抑郁症、疼痛、精神病、帕金森病、精神分裂症、焦虑症和注意力缺陷多动障碍（ADHD）的高潜力NK-3受体拮抗剂。
• ADENOSINE RECEPTOR LIGANDS
  申请人：——

  公开号：US20040204584A1

  公开（公告）日：2004-10-14

  The present invention relates to compounds of the general formula I 1 wherein R 1 , R 2 , R′, R″, n, m and o are defined herein, or a pharmaceutically acceptable salt thereof. It has been found that the compounds of general formula I are adenosine receptor ligands with a good affinity to the A 2A -receptor and a high selectivity to the A 1 - and A 3 receptors. These compounds have useful pharmacological activities.

  本发明涉及一般式I1的化合物，其中R1、R2、R′、R″、n、m和o如本文所定义，或其药学上可接受的盐。已发现一般式I的化合物是具有良好亲和力与A2A受体和高选择性对A1和A3受体的腺苷受体配体。这些化合物具有有用的药理活性。